| CGEN Stock | | | ILA 594.70 1.70 0.29% |
VP
Mr. John Hunter is Vice President Antibody Research and Development of Compugen Ltd. Dr. Hunter has worked for 18 years on different aspects of oncology drug development. Following graduation from UCSF, from 1996 to 2003, Dr. Hunter worked for Millennium Pharmaceuticals Inc., where he employed genomic approaches to identify novel drug targets in lung cancer. As a founding member of Millenniums Translational Medicine group he worked to develop clinical biomarkers for their Aurora kinase small molecule inhibitors. Following Dr. Hunter employment at Millennium, Dr. Hunter joined Xenogen Corporationration, where he worked as Senior Scientist in Oncology from 2004 to 2005. Dr. Hunter later joined XOMA Ltd., where from 2005 to 2012 he managed early stage antibody discovery for multiple therapeutic programs in oncology and inflammation. Dr. Hunter currently leads therapeutic antibody research and development efforts for Compugens portfolio of novel oncology targets. since 2012.
| Age | 52 |
| Tenure | 12 years |
| Phone | (972) 3 765 8555 |
| Web | www.cgen.com |
Compugen Management Efficiency
The company has return on total asset
(ROA) of
(0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.4394) %, meaning that it generated substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities.
Compugen has accumulated 2.85
M in total debt with debt to equity ratio
(D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Compugen has a current ratio of 9.41, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Compugen until it has trouble settling it off, either with new capital or with free cash flow. So, Compugen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Compugen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Compugen to invest in growth at high rates of return. When we think about Compugen's use of debt, we should always consider it together with cash and equity.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 68 people. Compugen (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 73 people.
Management Performance
Compugen Leadership Team
Elected by the shareholders, the Compugen's board of directors comprises two types of representatives: Compugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compugen. The board's role is to monitor Compugen's management team and ensure that shareholders' interests are well served. Compugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alberto Sessa, Chief Officer | |
| Michal Preminger, Director | |
| Rivka Schwartz, VP Discovery | |
| Paul Sekhri, Chairman of the Board | |
| Henry MD, VP Officer | |
| Arie Ovadia, Independent External Director | |
| Zurit Levine, Vice President - Research and Discovery | |
| Eran Perry, Director | |
| Ari Krashin, Chief Financial Officer | |
| Sanford Zweifach, Director | |
| Gilead Halevy, Director | |
| Anat CohenDayag, President, Chief Executive Officer, Director | |
| Ruth Arnon, Independent Director | |
| Yvonne Naughton, Head Communications | |
| Kinneret Savitsky, Director | |
| Henry Adewoye, Chief Medical Officer | |
| Dorit Amitay, VP HR | |
| Yair Aharonowitz, Independent External Director | |
| Eran Dor, Gen Sec | |
| JeanPierre Bizzari, Director | |
| Oliver Froescheis, Sr Devel | |
| John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc | |
Compugen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Information and Resources on Investing in Compugen Stock
When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For information on how to trade Compugen Stock refer to our
How to Trade Compugen Stock guide.
You can also try the
Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.